Search Within

Weinberg Fellows

Formats
  1. Meeting Abstract (1379)
  2. Journal Article (1159)
  3. Review (129)
  4. Editorial (65)
  5. Research Letter (36)
  6. Correspondence (26)
  7. Book Section (25)
  8. Guidelines (13)
  9. Conference Paper (2)
  10. Miscellaneous (2)
Groups
  1. Hematology-Oncology Fellows (2763)
  2. Department of Medicine (2720)
  3. Solid Tumor Oncology Division (2017)
  4. Hematologic Malignancies, Division of (1337)
  5. GSK Faculty (1233)
  6. Department of Pathology and Laboratory Medicine (988)

More Groups

People
  1. Michael Berger (220)
  2. Marc Ladanyi (198)
  3. Pedram Razavi (184)
  4. Michael Offin (177)
  5. Sergio Giralt (171)
  6. David Solit (169)

More People

Years
  1. 2025 (223)
  2. 2024 (414)
  3. 2023 (330)
  4. 2022 (377)
  5. 2021 (339)
  6. 2020 (323)

More Years

Publications
  1. Journal of Clinical Oncology (568)
  2. Blood (299)
  3. Annals of Oncology (107)
  4. Clinical Cancer Research (102)
  5. Journal of Thoracic Oncology (96)
  6. Cancer Research (87)

More Publications

Publishers
  1. American Society of Clinical Oncology (645)
  2. Elsevier Inc. (344)
  3. American Society of Hematology (339)
  4. American Association for Cancer Research (241)
  5. Nature Publishing Group (202)
  6. Oxford University Press (157)

More Publishers

Results (2836)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Use of real-world data (RWD) to assess the utility of cell-free circulating tumor DNA (cfDNA) in identifying resistance to early treatment in advanced breast cancer (aBC)
    Meeting Abstract

    Wander, S. A.; Weipert, C.; Liao, J.; Zhang, N.; Razavi, P.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Defining germline genetics of germ cell tumor: Implications for genetic testing and clinical management
    Meeting Abstract

    Truong, H.; Ravichandran, V.; Kemel, Y.; Knezevic, A.; Gleeson, J. P.; Benfante, N.; Bromberg, M.; Bolos, M.; Joseph, G.; Matulewicz, R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinicopathologic and mutational landscape of BRAF(V600E)-mutant non-small cell lung carcinoma
    Meeting Abstract

    Sui, J. S. Y.; Ladanyi, M.; Rudin, C. M.; Drilon, A. E.; Riely, G. J.; Kris, M. G.; Offin, M.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Impact of clonal hematopoiesis on tumor control following radiation therapy
    Meeting Abstract

    Tao, J.; Setton, J.; Vela, P. S.; Safonov, A. M.; Comen, E. A.; Braunstein, L. Z.; Reis-Filho, J. S.; Riaz, N.; Powell, S. N.; Levine, R. L.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A pilot study of trametinib in combination with paclitaxel in the treatment of anaplastic thyroid cancer
    Meeting Abstract

    Sherman, E. J.; Michel, L. S.; Kriplani, A.; Dunn, L.; Haque, S.; Bang, D.; Stein, S.; Pfister, D. G.; Ho, A. L.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase I/II study of prexasertib in combination with irinotecan in patients with relapsed/refractory desmoplastic small round cell tumor and rhabdomyosarcoma
    Meeting Abstract

    Slotkin, E. K.; Mauguen, A.; Ortiz, M. V.; Dela Cruz, F. S.; O'Donohue, T.; Kinnaman, M. D.; Meyers, P. A.; Wexler, L. H.; Rodriguez, S.; Avutu, V.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Allelic dosage of RB1 drives CDK4/6 inhibitor treatment resistance in metastatic breast cancer
    Meeting Abstract

    Safonov, A. M.; Bandlamudi, C.; Selenica, P.; Marra, A.; Ferraro, E.; Mandelker, D.; Solit, D. B.; Berger, M. F.; Norton, L.; Powell, S. N.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • FORTITUDE: Results of a phase 1a study of the novel transgene-armed and tumor-selective vector NG-350A with and without pembrolizumab (pembro)
    Meeting Abstract

    Rosen, L. S.; Camidge, D. R.; Khalil, D.; Lillie, T.; Carter, J.; Krige, D.; Davies, J.; Miles, D.; Patel, M.; Evilevitch, V.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1/2a TRESR trial (NCT04497116)
    Meeting Abstract

    Rosen, E.; Silverman, I. M.; Fontana, E.; Lee, E. K.; Spigel, D. R.; Højgaard, M.; Lheureux, S.; Mettu, N. B.; Carneiro, B. A.; Carter, L.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase I/II trial of the PD-1 inhibitor retifanlimab (R) in combination with gemcitabine and docetaxel (GD) as first-line therapy in patients (Pts) with advanced soft-tissue sarcoma (STS)
    Meeting Abstract

    Rosenbaum, E.; Qin, L. X.; Thornton, K. A.; Movva, S.; Nacev, B. A.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Avutu, V.; Chi, P.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save